CoChat

Fatal Fetal Outcome with the Combined Use of Valsartan and Atenolol

Briggs, Gerald G, Nageotte, Michael P · 2001 · The Annals of Pharmacotherapy
Cited by 53

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

AbstractOBJECTIVE:To report a case of anhydramnios, pulmonary hypoplasia, very small placenta, and fetal death in a pregnancy complicated by chronic hypertension and diabetes mellitus that had been treated through the first 24 weeks of gestation with valsartan and atenolol.CASE SUMMARY:A 40-year-old Hispanic woman with well-controlled chronic hypertension and diet-controlled type 2 diabetes mellitus was treated with valsartan and atenolol until pregnancy was diagnosed at 24 weeks' gestation. An ultrasound examination revealed normal fetal growth and anatomy but anhydramnios (amniotic fluid index 0). Valsartan was discontinued, and amniotic fluid volume normalized within two weeks. Intrauterine fetal death was documented at 33 weeks' gestation. Labor was induced, with the delivery of a stillborn female fetus with small, hypoplastic lungs (weight 41% of expected) and an extremely small, 148-g placenta (weight 48% of the 10th percentile for gestational age).DISCUSSION:The use of valsartan, a selective angiotensin II receptor antagonist (ARA), in human pregnancy has not been reported, but this class of agents would be expected to cause fetal toxicity similar to that observed with angiotensin-converting enzyme inhibitors. This toxicity includes reduced perfusion of the fetal kidneys, resulting in anuria, oligohydramnios, and subsequent pulmonary hypoplasia. The small hypoplastic lungs and very small placenta were probably a consequence of valsartan and atenolol combination therapy.CONCLUSIONS:Resolution of anhydramnios after discontinuing valsartan is evidence for ARA-induced fetal toxicity. The pulmonary hypoplasia observed in the stillborn infant was a direct result of the severe oligohydramnios. The cause of fetal death nine weeks later is uncertain, but because the woman's chronic hypertension and diabetes were well controlled, we believe the primary cause was chronic placental insufficiency resulting from the previous combination of valsartan and atenolol. ResumenOBJETIVO:Reportar un caso de anhidramnios, hipoplasia pulmonar, placenta muy pequeña, y muerte fetal en un embarazo complicado por hipertensión crónica y diabetes mellitus que había sido tratado en las primeras 24 semanas de gestación con valsartan y atenolol.RESUMEN DEL CASO:Una mujer de 40 años con hipertensión crónica bien controlada y diabetes mellitus tipo 2 controlada con dieta fue tratada con valsartan y atenolol hasta que se diagnosticó el embarazo a las 24 semanas de gestación. Una prueba de ultrasonido reveló una anatomia y crecimiento fetal normal pero con anhidramnios (índice de fluído amniótico cero). Se descontinuó el valsartan, y el volumen del fluído amniótico se normalizó en dos semanas. Se documentó muerte fetal intrauterina a las 33 semanas de gestación. Se indujo el parto de un feto femenino muerto con pulmones hipoplásicos pequeños (41% del peso esperado) y una placenta de 148 g extremadamente pequeña (peso 48% de la 10a percentila para la edad gestacional).DISCUSIÓN:El uso de valsartan, un antagonista selectivo de los receptores de angiotensina II (ARA), no ha sido reportado durante el embarazo. Sin embargo, puede esperarse que esta clase de agentes pueda causar toxicidad fetal similar a la observada con los inhibidores de la enzima convertidora de angiotensina. Esta toxicidad incluye perfusión reducida a los riñones del feto resultando en anuria, oligohidramnios, e hipoplasia pulmonar subsiguiente. Los pulmones hipoplásicos pequeños y la placenta bien pequeña fueron consecuencias de la combinación de valsartan y atenolol.CONCLUSIONES:La resolución de la anhidramnios después de descontinuar valsartan es evidencia de toxicidad fetal inducida por el ARA. La hipoplasia pulmonar observada en el infante muerto fue resultado directo de la oligohidramnios severa. La causa de muerte fetal nueve semanas después no está clara. Sin embargo, los autores creen que debido a que la hipertensión crónica y la diabetes de la paciente estaban bien controladas, la causa primaria fue insuficiencia placental crónica como resultado de la combinación previa de valsartan y atenolol. RésuméOBJECTIF:Il s'agit d'un cas d'anhydramnios, d'hyperplasie pulmonaire, d'une très petit placenta, et d'une mort fétale dans une grossesse compliquée d'une hypertension chronique et d'un diabète, qui a été traitée durant les 24 premières semaines de gestation avec du valsartan (V) et de l'atenolol (A).RÉSUMÉ:Il s'agit d'une femme de 40 ans avec une hypertension chronique bien contrôlée par le V et l'A et un diabète de type 2 contrôlé par la diète jusqu'à la 24leme semaine de gestation, moment ou la grossesse a été diagostiquée. Un examen par ultrason a révélé une croissance fétale ainsi qu'une anatomie normale mais un anhydramnios (un index de fluide amniotique à zéro [IFA]). Le V fut arrêté et le volume de fluide amniotique s'est normalisé en deux semaines. Une mort fétale intrautérine fut constatée à la 33leme semaine de gestation. Le travail fut induit avec comme ré

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1345/1542-6270(2001)035<0859:ffowtc>2.0.co;2

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 53

Metadata

Authors
Briggs, G. G., & Nageotte, M. P.
Venue
The Annals of Pharmacotherapy
Published
2001-07
Volume
35
Issue
7-8
Pages
859-861
ISSN
  • 0012-6578 (ISSN-L)
  • 1060-0280
  • 1542-6270
OpenAlex
W2169524479
Cited by
53
References
1
FWCI
4.43
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fatal Fetal Outcome with the Combined Use of Valsartan and Atenolol. https://app.cochat.ai/papers/10.1345/1542-6270(2001)035%3C0859:ffowtc%3E2.0.co;2
The paper
Briggs, G. G., & Nageotte, M. P. (2001). Fatal Fetal Outcome with the Combined Use of Valsartan and Atenolol. The Annals of Pharmacotherapy. https://doi.org/10.1345/1542-6270(2001)035%3C0859%3Affowtc%3E2.0.co%3B2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.